Linzess, with the active ingredient linaclotide, is a medication prescribed to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults [1]. The 72 mcg dosage is one of the available strengths for this medication.
How does Linzess work for constipation?
Linzess works by increasing fluid secretion and accelerating intestinal transit. Linaclotide activates guanylate cyclase-C (GC-C) on the luminal surface of intestinal cells. This activation leads to an increase in cyclic guanosine monophosphate (cGMP), which stimulates bicarbonate and chloride secretion into the intestinal lumen. The increased fluid softens stool and promotes its passage [2].
What is the difference between Linzess 72 mcg and other strengths?
Linzess is available in several strengths: 72 mcg, 145 mcg, and 290 mcg [3]. The 72 mcg dose is typically prescribed for patients with IBS-C and CIC. Dosing is based on the indication and patient response. It is important to follow a healthcare provider's specific prescription for the correct strength and usage.
When does the patent for Linzess expire?
The patent landscape for Linzess is complex, involving multiple patents covering composition of matter, method of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiry dates. For specific details on Linzess patent expiry, one would typically consult resources that specialize in drug patent information [4].
What are the potential side effects of Linzess?
The most common side effect reported with Linzess is diarrhea [1]. Other potential side effects include abdominal pain, flatulence, and headache. Patients experiencing severe or persistent diarrhea should contact their healthcare provider.
Who manufactures Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [1].